No summary available.

Welcome to another special episode of the Marketing Vanguard podcast. Today, ADWEEK chief experience officer Jenny Rooney welcomes Claudine Patel, Sanofi''s chief marketing officer for consumer healthcare North America. Sanofi is the world''s sixth-largest pharmaceutical and healthcare company and is headquartered in Paris. They discuss how Sanofi''s brands, which include Allegra, Dulcolax, and Gold Bond,…

In the ever-evolving and intensely competitive business landscape, conducting a thorough company analysis is of utmost importance for investors and industry followers. In this article, we will carry out an in-depth industry comparison, assessing Regeneron Pharmaceuticals (NASDAQ: REGN ) alongside its primary competitors in the Biotechnology industry. By meticulously examining key financial metrics, market positioning, and growth prospects, we aim to offer valuable insights to investors and shed light on company''s performance within the industry. Regeneron Pharmaceuticals Background Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

The Abu Dhabi fund is among the most active investors in private equity-led transactions

BURLINGAME, CALIFORNIA, UNITED STATES, August 22, 2024 /⁨EINPresswire.com⁩/ -- Latest Report, titled “GLP-1 Receptor Agonist Market” Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031, by Coherent Market Insights offers a comprehensive …

DataM Intelligence has published a new research report on "Colorectal Cancer Drugs Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and

It''s estimated that more than 31,000 people in South Africa live with Type 1 diabetes and require full insulin replacement therapy, with multiple daily injections

Earlier this month, the FDA approved ARS Pharmaceuticals Inc’s (NASDAQ: SPRY ) neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are life-threatening (anaphylaxis), for adult and pediatric patients . ARS Pharma’s Neffy is to be an alternative to EpiPen and other autoinjectors like Sanofi SA’s (NASDAQ: SNY ) Auvi-Q filled with epinephrine. Also Read: Allergic Reaction Focused ARS Pharmaceuticals’ Lead Candidate Shows Efficacy In Skin Disorder . Cantor Fitzgerald initiated coverage on ARS Pharmaceuticals, noting that the “media coverage of … Full story available on Benzinga.com

Visualizing The Cost Of Insulin In The US (2004-2024) Over the past few decades, the cost of insulin in the United States skyrocketed, affecting millions of people with diabetes relying on it every day. Insulin is produced by three major manufacturers in the U.S.—Eli Lilly, Novo Nordisk, and Sanofi. This infographic by Visual Capitalist''s Pernia Jamshed and Shabeeb Hammad focuses on the drastic price rise of Eli Lilly’s rapid-acting insulin, Humalog, using data sourced from Pharmaceutical Technology , NBC News , and Eli Lilly . Cost of Insulin from 2004 to 2024 Humalog is one of the most well-known insulin brands globally. It is a fast-acting insulin that controls blood sugar levels in people with type 1 and type 2 diabetes. In 1996, when it was first introduced, a 10 mL vial of Humalog cost $21.23. A decade later, this price shot up by over 200% to $70 USD. Over the 10 years from 2006 to 2016, the cost of insulin in the U.S. climbed to $255 for 10 mL Humalog, a 264% increase . By 2017 it reached $275 before increasing public scrutiny and legislation to cap prices in certain states stopped the climb.

No summary available.